N/A
Completed N=110
European Union (EU) Post-Market Study on Easyband®
Source: ClinicalTrials.gov NCT00948246 ↗Enrolled (actual)
110
Serious AEs
26.4%
Results posted
Nov 2012
Primary outcomePrimary: Feasibility and Ease of Implantation — 71.8; 81.8; 88.2 percentage of subjects
Summary
The purpose of this study is to collect additional safety, performance and effectiveness data of the Easyband gastric band medical device in the treatment of morbid obesity in 4 European countries where the device is a CE marked approved product.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Feasibility and Ease of Implantation |
71.8; 81.8; 88.2 | — |
| SECONDARY % Excess Weight Loss |
30.73 | — |
| SECONDARY Change in BMI |
-7.23 | — |
| SECONDARY Change in Weight |
-20.70 | — |
Eligibility Criteria
Inclusion Criteria
- Demonstrated failure in losing weight with non-invasive therapies
- BMI ≥ 40 kg/m2, or BMI ≥ 35 kg/m2 and < 40 kg/m2 with one or more significant medical conditions related to obesity
Exclusion Criteria
- patients with BMI greater than 60 kg/m2
- patients who are not indicated for laparoscopic bariatric surgery
- patients with known allergies to implant materials such as silicone and PEEK
- patients whose abdominal structures have been damaged during preceding surgical procedures
- pregnant women
- patients under the age of 18 years
- patients treated with steroids
- patients addicted to alcohol or drugs, or who are mentally unstable, or who may not comply with the follow-up and dietary restrictions
- patients already implanted with a device sensitive to radio-frequency emissions such as implanted pacemaker, defibrillators, cochlear implants, implantable pumps etc
Data sourced from ClinicalTrials.gov (NCT00948246). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.